Cargando…
Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study
OBJECTIVE: Midodrine hydrochloride is a short-acting pressor agent that raises blood pressure in the upright position in patients with orthostatic hypotension. The US Food and Drug Administration’s Subpart H approval, under which midodrine was initially approved, requires post-marketing studies to c...
Autores principales: | Smith, William, Wan, Hong, Much, David, Robinson, Antoine G., Martin, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951503/ https://www.ncbi.nlm.nih.gov/pubmed/27372462 http://dx.doi.org/10.1007/s10286-016-0363-9 |
Ejemplares similares
-
Midodrine for orthostatic hypotension
Publicado: (2020) -
Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
Publicado: (2020) -
Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
por: Byun, Jung‐Ick, et al.
Publicado: (2019) -
Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease
por: Kremens, Daniel, et al.
Publicado: (2017) -
Fludrocortisone Is Associated With a Higher Risk of All‐Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension
por: Grijalva, Carlos G., et al.
Publicado: (2017)